CGT Space Faces Some Challenges, but There ‘Still Is a Place’ for Therapies
-
Mar 13, 2025
The cell and gene therapy (CGT) space seems to be a bit of a mixed bag recently. While last year’s accomplishments included FDA approvals of two new first-in-class treatments for solid tumors and the first chimeric antigen receptor T cell (CAR-T) therapy since 2022, on back-to-back days last month, the news was more downbeat.
On Feb. 20, reports that Pfizer Inc. was discontinuing its hemophilia B gene therapy Beqvez (fidanacogene elaparvovec) globally were first publicized and later confirmed by the drugmaker. The FDA had approved the single-dose $3.5 million treatment less than a year prior, on April 25, 2024.
Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.